ClearPoint Neuro stock (US18507C1099): MAK Capital discloses 6.3% passive stake in CLPT

ClearPoint Neuro has attracted a new notable shareholder: MAK Capital reported a 6.3% passive stake in the medtech company in a recent SEC filing, drawing fresh attention to the CLPT stock after a volatile trading phase.

ClearPoint Neuro stock has moved back into focus after an updated Schedule 13G/A filing showed that MAK Capital and related entities now hold a passive 6.3% stake in the company. The filing, which details ownership of about 1.9 million shares as of May 15, 2026, highlights renewed institutional interest in the specialist in MRI-guided neurosurgery technology, according to StockTitan as of 05/15/2026.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ClearPoint Neuro, Inc.
• Sector/industry: Medical technology / neurosurgery
• Headquarters/country: Solana Beach, California, United States
• Core markets: Neurosurgical centers in North America and selected international hospitals
• Key revenue drivers: MRI-guided neurosurgical platforms, disposable surgical products and related services
• Home exchange/listing venue: Nasdaq (ticker: CLPT)
• Trading currency: USD

ClearPoint Neuro: core business model

ClearPoint Neuro focuses on minimally invasive neurosurgical procedures that are guided by real-time MRI imaging. The company’s platform is designed to help surgeons navigate instruments precisely within the brain, aiming to improve targeting accuracy and reduce trauma compared with traditional open procedures. This technology addresses complex indications where millimeter-level precision can be critical for patient outcomes.

The business model combines capital equipment with recurring revenue from disposables and procedure-related services. Hospitals and specialized neurosurgical centers typically install the ClearPoint system and then purchase single-use instruments, cannulae and related accessories for each procedure. This mix of one-off and recurring revenue is common in medtech and, if procedure volumes grow, can lead to increasing operating leverage over time.

Beyond its core neurosurgery use cases, ClearPoint Neuro also works with biopharmaceutical partners on procedures such as targeted delivery of gene and cell therapies to the brain. These collaborations can involve using the platform in clinical trials, which may generate service revenue and position the company for potential long-term adoption if such therapies reach commercial stages, according to company descriptions in recent investor materials on its website ClearPoint Neuro IR as of 03/2026.

Main revenue and product drivers for ClearPoint Neuro

The ClearPoint system itself is a key driver, but much of the revenue potential lies in procedure-based consumables. Each neurosurgical case typically uses catheters, guides and other single-use tools designed specifically for the system. As hospitals increase the number of MRI-guided procedures, the recurring revenue base can expand even if the installed system count grows more slowly.

Service contracts and training also contribute to the revenue mix. Hospitals often require clinical support and maintenance to keep complex imaging and navigation systems operating reliably. ClearPoint Neuro provides training for surgical teams and intraoperative support in some cases, which can strengthen customer relationships and support adoption. These elements can be particularly important when centers introduce new types of MRI-guided procedures.

In addition, the company positions its platform as an enabling technology for advanced therapies in neurology. When biopharma partners test new treatments that must be delivered to specific areas of the brain, ClearPoint’s MRI-guided approach can support precise administration. While revenues from these collaborations can be volatile and project-based, they offer exposure to a potential future wave of neuro-focused therapeutics, as highlighted in past corporate presentations referenced in its investor relations materials ClearPoint Neuro news as of 02/2026.

Institutional interest: MAK Capital’s 6.3% passive stake

The latest visible trigger for ClearPoint Neuro stock is the updated Schedule 13G/A filed with the U.S. Securities and Exchange Commission. In this document, MAK Fund, MAK Capital One and Michael A. Kaufman disclose beneficial ownership of 1,901,489 common shares, representing 6.3% of the company’s outstanding stock based on 29,989,563 shares as of May 7, 2026, according to StockTitan as of 05/15/2026.

The filing is notable because it classifies the position as passive, using a Schedule 13G/A instead of an activist-style Schedule 13D. That means the reporting entities state they do not currently intend to seek control or influence management in a way that would require the more detailed activist disclosure. For existing shareholders, the presence of an institutional investor with more than 5% of the shares can still be significant, as it signals a degree of conviction in the company’s long-term prospects.

The document indicates shared voting and dispositive power over the reported shares, suggesting they are managed across related entities under common control rather than being personally owned by a single individual. While the filing does not provide price levels or a detailed investment thesis, the size of the stake implies a meaningful capital allocation decision within the MAK Capital group. Such filings also increase transparency for the market, as other investors can see changes in the shareholder base over time.

Recent share price behavior and volatility

ClearPoint Neuro’s share price has been volatile, typical for small and mid-cap medtech names. External price trackers show periods of sharp daily moves, underlining that CLPT can respond strongly to news and technical factors. For example, independent chart services documented that the stock has seen wide intraday ranges in recent sessions, with swings of several percentage points between daily highs and lows, according to commentary on a trading analytics portal updated in May 2026 StockInvest.us as of 05/15/2026.

Such volatility can reflect a combination of factors: relatively low average daily trading volume, concentrated institutional holdings and a news flow that alternates between clinical progress, capital market developments and technical trading levels. For traders, this environment may create opportunities for short-term price moves, while long-term investors typically focus more on revenue growth, margin trends and adoption of the technology in neurosurgical centers.

It is also relevant that small-cap healthcare stocks can be sensitive to broader market sentiment around risk assets, interest rates and biotech or medtech funding conditions. In phases when investors move away from higher-risk growth names, CLPT can experience amplified moves, regardless of company-specific news. Conversely, positive sector sentiment or favorable clinical data in related fields may support the valuation. These dynamics mean that price action around ClearPoint Neuro often reflects both company developments and macro factors.

Industry trends and competitive position

ClearPoint Neuro operates in a specialized segment of the medical technology market: image-guided neurosurgery and neurointerventional procedures. The broader trend in surgery over the last decade has favored minimally invasive approaches, using imaging and navigation to reduce open surgery where possible. MRI-guided systems remain a niche within this overall trend because they require integration with high-end imaging suites, but they can offer unique advantages in soft-tissue visualization.

Competition comes from companies offering intraoperative MRI solutions, stereotactic neurosurgery systems and other navigation technologies that integrate with operating rooms. Large diversified medtech players often serve neurosurgeons with multiple product lines, from implants to navigation software. In this environment, ClearPoint Neuro differentiates itself through its focus on real-time MRI guidance and its specialization in neuro applications, rather than offering a broad surgical portfolio.

The company’s collaborations with biopharma developers of gene and cell therapies may also be strategically important. If targeted delivery of such therapies becomes more widely adopted, neuro-navigation tools that provide precise and reproducible access to brain regions could become integral to treatment protocols. In that scenario, ClearPoint Neuro’s positioning as an enabling technology provider could support its competitive standing, particularly if its platform becomes embedded in clinical trial protocols and eventual product labels.

Why ClearPoint Neuro matters for US investors

For US investors, ClearPoint Neuro is primarily relevant as a Nasdaq-listed medtech name with exposure to neurosurgery and advanced neurotherapies. The company’s base of operations in California and its focus on North American hospitals mean that developments in the US healthcare market, reimbursement environment and hospital capital spending directly influence its business. Changes in US regulation for neurosurgical devices or gene therapy trials can also have a direct impact.

From a portfolio perspective, CLPT provides targeted exposure to the neuroscience and neurosurgery segment, which can behave differently from broader healthcare indices. While large pharmaceutical and diversified medical device companies may be more influenced by primary care trends and chronic disease management, ClearPoint Neuro’s fortunes are closely tied to complex procedures and high-end imaging infrastructure. For some investors, this offers a way to participate in potential advances in brain disease treatment that are not directly captured by broader healthcare ETFs.

However, this specialization also entails concentration risk. Revenues depend on a relatively narrow set of procedures and hospital budgets, and the company does not have the diversification of larger healthcare groups. US-based investors who follow small and mid-cap growth names in the medical technology space often monitor CLPT alongside other neurosurgical and interventional technology providers to assess relative adoption, balance sheet strength and progress toward profitability.

Risks and open questions

ClearPoint Neuro faces several typical risks for a specialized medtech company. First, adoption of its platform depends on hospitals’ willingness to invest in MRI-guided neurosurgical capabilities, which can be capital-intensive. Budget constraints or shifts in hospital priorities could delay new installations or limit procedure growth. Second, reimbursement pathways for new procedures and advanced therapies can be complex, and payor decisions may influence how quickly new techniques become mainstream.

Regulatory and clinical trial risks also play a role. For collaborations that involve gene or cell therapy delivery, outcomes in clinical studies can affect the perceived value of the platform. Setbacks in partner pipeline programs may reduce near-term procedure volumes, even if the underlying navigation technology remains validated. Furthermore, competition from alternative navigation approaches could limit pricing power or require ongoing investment in product development to maintain differentiation.

From a capital markets perspective, small-cap medtech firms often rely on periodic equity raises to fund growth and R&D. Market conditions, share price volatility and investor appetite for healthcare growth stories can therefore influence dilution over time. The presence of institutional investors such as MAK Capital provides some validation of the investment case, but it does not eliminate the fundamental risks associated with development-stage or growth-stage medical technology businesses.

Conclusion

ClearPoint Neuro sits at the intersection of neurosurgery, imaging and advanced neurotherapies, with a business model built around MRI-guided procedures and recurring disposable sales. The recent Schedule 13G/A filing showing a 6.3% passive stake by MAK Capital underscores that institutional investors are paying attention to the story, even as the share price experiences significant volatility. For market participants, the key questions center on the pace of hospital adoption, traction in biopharma partnerships and the company’s ability to manage risks related to funding, competition and regulatory developments. How these factors evolve will likely shape CLPT’s long-term role in portfolios focused on US healthcare innovation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.